News|Articles|August 2, 2021

Pharmaceutical Technology

  • Pharmaceutical Technology, August 2021 Issue
  • Volume 45
  • Issue 8

Grouping Products and Equipment for a Worst-Case Cleaning Validation Study

A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.

Peer-Reviewed

Submitted: December 1, 2020
Accepted: February 5, 2021

Abstract

Cleaning validation requires a significant effort to design a strategic and effective program that is defendable with regulatory agencies. Of primary concern is what to validate. A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.

Click here to read Grouping Products and Equipment for a Worst-Case Cleaning Validation Study (PDF).

About the author

Richard Forsyth is a Principal Consultant with Forsyth Pharmaceutical Consulting.

Article Details

Pharmaceutical Technology
Vol. 45, No. 8
August 2021
Pages: 44–51

Citation

When referring to this article, please cite it as R. Forsyth, "Grouping Products and Equipment for a Worst-Case Cleaning Validation Study," Pharmaceutical Technology 45 (8) 2021.


Related to this article

Intravenous therapy; drip chamber in focus against a colorful background | Image Credit: ©Anna Jurkovska -stock.adobe.com
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Ask the Expert: Post-Approval Changes
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.